Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Risky Business: Understanding and Attenuating Risk Associated with Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis

Patient Resources - CME Outfitters has designed these videos, resources, and tools to address frequently asked questions and to help patients increase their knowledge about their MS. It is our goal that the education will contribute to improved and informed discussions between patients and health care providers in the management of MS.

presurvey

neuroscienceCME Live and On Demand

Premiere Date: Wednesday, December 9, 2015

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Social Workers (NASW)
  4. Certified Case Managers (CCMC)
  5. Pharmacists (ACPE)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, December 9, 2016
Note: Credit Is No Longer Available

Faculty


Michael K. Racke, MDMichael K. Racke, MD (Moderator)
Professor of Neurology and Neuroscience
Wexler Medical Center at The Ohio State University Medical Center
Columbus, OH

Patricia K. Coyle, MD, FAAN, FANAPatricia K. Coyle, MD, FAAN, FANA 
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Brant J. Oliver, PhD, MS, MPH, APRN-BCBrant J. Oliver, PhD, MS, MPH, APRN-BC 
Assistant Professor, School of Nursing
MHG Institute of Health Professions
Boston, MA
Adjunct Assistant Professor
Dartmouth Institute of Health Policy & Clinical Practice
Geisel School of Medicine
Dartmouth College
Hanover, NH
VT Neurobehavioral Specialists
Multiple Sclerosis Specialty Care Program
Concord Hospital
Concord, NH

Statement of Need

Multiple sclerosis (MS) strikes people in the prime of their lives, affecting upwards of 400,000 people in the United States and 2.5 million worldwide.1 However, a diagnosis of MS is no longer a sentence of doom; “the MS landscape has been comprehensively and irreversibly transformed by progress”2 in understanding the pathophysiology of the disease and the development of targeted therapy. As new therapeutic options become available, establishing effective patient-centric treatment plans, based upon newly identified targets and incorporating mechanism of action, will be increasingly essential to achieving optimum quality of life for all of these individuals.

In this neuroscienceCME Live and On Demand faculty will share the evidence and their insights with health care providers to enable them to collaboratively engage patients in a discussion about their disease and develop shared treatment goals to improve outcomes in patients with MS.


  1. Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Rev Clin Immunol. 2015;11(1):93-108. PMID: 25495182.
  2. Du Pasquier RA, Pinschewer DD, Merkler D. Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs. 2014;28(6):535-558. PMID: 24723124.

Activity Goal

Integrate shared-decision making into practice considering patients' goals of treatment to develop a treatment strategy based on the evidence.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • When selecting disease-modifying therapy for a specific patient, include the mechanism of action of each agent and its safety profile into the decision-making process.
  • Identify factors that are of primary importance as targets of treatment in collaboration with your patients with MS.
  • Incorporate a point-of-care decision tool that can be used to explain individual risk and to identify factors that may affect a patients’ risk tolerance as part of a patient-centered approach to care.

The following learning objectives pertain only to those requesting CNE credit:

  • Evaluate disease-modifying therapy for patients with MS, including the mechanism of action of each agent and its safety profile.
  • Describe factors that are of primary imporatance as targets of treatment for patients with MS.
  • Review a point-of-care decision tool that can be used to explain individual risk and to identify factors that may affect a patients’ risk tolerance as part of a patient-centered approach to care.

Financial Support

Supported by educational grants from Genzyme, a Sanofi Company and Novartis Pharmaceuticals Corporation.

Target Audience

Neurologists, general practitioners, NP, PA, nurses, pharmacists and other health care professionals interested in multiple sclerosis.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

NASW Credit (Social Workers):
This program is Approved by the National Association of Social Workers (Approval # 886407722-0) for 1.5 Social Work continuing education contact hours.

CCMC Credit (Certified Case Managers):
This program has been approved for 1.5 hours by the Commission for Case Manager Certification (CCMC).

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-15-028-L01-P (live programs)
0376-0000-15-028-H01-P (recorded programs)
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST19040 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Racke has disclosed that he has received grant/research support from National Institutes of Health; National Multiple Sclerosis Society; Novartis Corporation; and Roche (pharma support is for clinical trials). He serves as a consultant to EMD Serono, Inc.; Roche/Genentech, Inc.; and Novartis Corporation.

Dr. Coyle has disclosed that she has received grant/research support from Actelion Pharmaceuticals US, Inc.; Biogen Idec, Inc.; Genentech, Inc./Roche; Novartis; and Opexa Therapeutics, Inc. She serves as a consultant to AbbVie Inc.; Accordant; Acorda Therapeutics; Biogen; Genentech, Inc./Roche; Genzyme Corporation/sanofi-aventis U.S. LLC; Novartis; EMD Serono, Inc.; and Teva Pharmaceuticals USA

Dr. Oliver has disclosed that he has received grant/research support from Teva Neuroscience, Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.

Catherine Murray (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Disclosures have been obtained from CME Outfitters staff: No disclosures to report.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, Genzyme, a Sanofi Company and Novartis Pharmaceuticals Corporation do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

TV-087-120915-90

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download